Methylprednisolone Sodium Succinate Injection, Powder, For Solution
NDC Package 70518-4345-0

11-digit billing NDC: 70518434500

Package Information

Methylprednisolone Sodium Succinate injection is methylprednisolone Sodium Succinate Sterile Powder is contraindicated:in systemic fungal infections and patients with known hypersensitivity to the product and its constituents; The methylprednisolone sodium succinate for injection 40 mg presentation includes lactose monohydrate produced from cow’s milk. This formulation utilizes a injection, powder, for solution delivery system. Marketed by Remedyrepack Inc., this product is identified by NDC 70518-4345 and is authorized under FDA application ANDA203125.

Identification & Billing

NDC Package Code
70518-4345-0
Package Description
25 VIAL, SINGLE-DOSE in 1 CARTON / 1 INJECTION, POWDER, FOR SOLUTION in 1 VIAL, SINGLE-DOSE (70518-4345-1)
Product Code
11-Digit Billing Format
70518434500
RxNorm Crosswalk
  • RxCUI: 1743704 - methylPREDNISolone sodium succinate 125 MG Injection
  • RxCUI: 1743704 - methylprednisolone 125 MG Injection
  • RxCUI: 1743704 - methylprednisolone (as methylprednisolone sodium succinate) 125 MG Injection

Clinical Specifications

Proprietary Name
Methylprednisolone Sodium Succinate
Non-Proprietary Name
Methylprednisolone Sodium Succinate
Substance Name
Methylprednisolone Sodium Succinate
Dosage Form
Injection, Powder, For Solution - A sterile preparation intended for reconstitution to form a solution for parenteral use.
Administration Route
  • Intramuscular - Administration within a muscle.
  • Intravenous - Administration within or into a vein or veins.
Usage Information
Methylprednisolone Sodium Succinate Sterile Powder is contraindicated:in systemic fungal infections and patients with known hypersensitivity to the product and its constituents; The methylprednisolone sodium succinate for injection 40 mg presentation includes lactose monohydrate produced from cow’s milk. This presentation is therefore contraindicated in patients with a known or suspected hypersensitivity to cow’s milk or its components or other dairy products because it may contain trace amounts of milk ingredients.for intrathecal administration. Reports of severe medical events have been associated with this route of administration.Intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura.Additional contraindication for the use of Methylprednisolone Sodium Succinate Sterile Powder preserved with benzyl alcohol:Formulations preserved with benzyl alcohol are contraindicated for use in premature infants (see WARNINGSand PRECAUTIONS, Pediatric Use).

Regulatory & Marketing

Labeler Name
Remedyrepack Inc.
Product Type
Human Prescription Drug
FDA Application #
ANDA203125
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
05-27-2025
Listing Expiration
12-31-2027
Exclude Flag
N
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 70518-4345-0 identifies a specific commercial package of 25 vial, single-dose in 1 carton / 1 injection, powder, for solution in 1 vial, single-dose (70518-4345-1) of Methylprednisolone Sodium Succinate, a human prescription drug labeled by Remedyrepack Inc.. This injection, powder, for solution is formulated for intramuscular; intravenous use and contains methylprednisolone sodium succinate as the active substance.

Is this product currently listed with the FDA?

Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Remedyrepack Inc. on May 27, 2025. The current certification is valid through December 31, 2027.

How is this Remedyrepack Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 70518434500. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-4-1)
70518-4345-0
11-Digit CMS (5-4-2)
70518-4345-00

Note: The zero is added to the Package segment to maintain the 5-4-2 structure.